Global Pseudorabies Virus Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pseudorabies Virus Vaccine Market Report, History and Forecast 2024-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Porcine pseudorabies is an acute infectious disease of pigs caused by Pseudorabies virus (PrV). The disease is fulminant in pigs. It can cause abortion of pregnant sows, stillbirth, infertility of boars, death of a large number of newborn piglets, difficulty in breathing of fattening pigs, and stagnant growth. It is one of the major infectious diseases that harm the global pig industry.
Pseudorabies Virus Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pseudorabies Virus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Government Tender and Market Sales are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pseudorabies Virus Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pseudorabies Virus Vaccine key manufacturers include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd. are top 3 players and held % sales share in total in 2022.
Pseudorabies Virus Vaccine can be divided into Inactivated Vaccine, Naturally Deficient Attenuated Vaccine and Genetic Engineering Vaccine,, etc. Inactivated Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Pseudorabies Virus Vaccine is widely used in various fields, such as Government Tender and Market Sales, etc. Government Tender provides greatest supports to the Pseudorabies Virus Vaccine industry development. In 2022, global % sales of Pseudorabies Virus Vaccine went into Government Tender filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pseudorabies Virus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Merck
Merial Limited
Boehringer Ingelheim Animal Health (USA) Co., Ltd.
Zoetis
Hipra
Anhui Divinity Biological Products
Wuhan Keqian Biological Co., Ltd.
China Biotechnology Co., Ltd.
CHINA ANIMAL HUSBANDRY INDUSTRY
Sichuan Huashen
Haley
Tianbang
Dabei Nong
Harvey
Preh Bio
Jiangsu Nannong High-Tech Co.
Guangxi Liyuan Biological Co., Ltd.
Jilin Zhengye Bioengineering Group
Jilin Heyuan Biological Engineering Co., Ltd.
Huapai Biological Engineering Group Co., Ltd.
Beijing Xinde Weite Technology Co., Ltd.
Beijing Veterinary Biopharmaceutical Factory
Qilu Animal Health Products Co., Ltd.
Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
Yunnan Biopharmaceutical Co.
Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
Liaoning Yikang Biological Co., Ltd.
Shanghui Huahong Biological Engineering Co., Ltd.
Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Segment by Type
Inactivated Vaccine
Naturally Deficient Attenuated Vaccine
Genetic Engineering Vaccine
Government Tender
Market Sales
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pseudorabies Virus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pseudorabies Virus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pseudorabies Virus Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pseudorabies Virus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pseudorabies Virus Vaccine introduction, etc. Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pseudorabies Virus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Pseudorabies Virus Vaccine report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Pseudorabies Virus Vaccine market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Demand from Government Tender and Market Sales are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Pseudorabies Virus Vaccine industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Pseudorabies Virus Vaccine key manufacturers include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd. are top 3 players and held % sales share in total in 2022.
Pseudorabies Virus Vaccine can be divided into Inactivated Vaccine, Naturally Deficient Attenuated Vaccine and Genetic Engineering Vaccine,, etc. Inactivated Vaccine is the mainstream product in the market, accounting for % sales share globally in 2022.
Pseudorabies Virus Vaccine is widely used in various fields, such as Government Tender and Market Sales, etc. Government Tender provides greatest supports to the Pseudorabies Virus Vaccine industry development. In 2022, global % sales of Pseudorabies Virus Vaccine went into Government Tender filed.
Report Scope
This report, based on historical analysis (2024-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pseudorabies Virus Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Merck
Merial Limited
Boehringer Ingelheim Animal Health (USA) Co., Ltd.
Zoetis
Hipra
Anhui Divinity Biological Products
Wuhan Keqian Biological Co., Ltd.
China Biotechnology Co., Ltd.
CHINA ANIMAL HUSBANDRY INDUSTRY
Sichuan Huashen
Haley
Tianbang
Dabei Nong
Harvey
Preh Bio
Jiangsu Nannong High-Tech Co.
Guangxi Liyuan Biological Co., Ltd.
Jilin Zhengye Bioengineering Group
Jilin Heyuan Biological Engineering Co., Ltd.
Huapai Biological Engineering Group Co., Ltd.
Beijing Xinde Weite Technology Co., Ltd.
Beijing Veterinary Biopharmaceutical Factory
Qilu Animal Health Products Co., Ltd.
Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
Yunnan Biopharmaceutical Co.
Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
Liaoning Yikang Biological Co., Ltd.
Shanghui Huahong Biological Engineering Co., Ltd.
Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Segment by Type
Inactivated Vaccine
Naturally Deficient Attenuated Vaccine
Genetic Engineering Vaccine
Segment by Application
Government Tender
Market Sales
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Each chapter of the report provides detailed information for readers to understand the Pseudorabies Virus Vaccine market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Pseudorabies Virus Vaccine, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Pseudorabies Virus Vaccine industry.
Chapter 3Historical (2024-2022) and forecast (2024-2034) volume and revenue analysis of Pseudorabies Virus Vaccine in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2024 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Pseudorabies Virus Vaccine introduction, etc. Pseudorabies Virus Vaccine Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Pseudorabies Virus Vaccine market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices